Cymbalta is one of the most commonly prescribed and costly drugs for chronic pain and/or depression and it is often included in Medicare set aside (MSA) allocation reports. Fortunately, the patent for Cymbalta expired in early December and the generic form, duloxetine hydrochloride, is now available. The generic pricing has resulted in a significant decrease in cost, which in turn should result in reductions of MSA drug costs when Cymbalta has been prescribed. Depending on the dosage, there can be a savings of $1.55 to $1.75 per pill, and when calculated over a claimants’ lifetime there will be a substantial savings in the medication costs. Please be aware that this applies to any existing MSAs so this pricing change may warrant a revision in the report.
Your Medicare Compliance Advocates
Monday, January 6, 2014
Cymbalta Goes Generic
Cymbalta is one of the most commonly prescribed and costly drugs for chronic pain and/or depression and it is often included in Medicare set aside (MSA) allocation reports. Fortunately, the patent for Cymbalta expired in early December and the generic form, duloxetine hydrochloride, is now available. The generic pricing has resulted in a significant decrease in cost, which in turn should result in reductions of MSA drug costs when Cymbalta has been prescribed. Depending on the dosage, there can be a savings of $1.55 to $1.75 per pill, and when calculated over a claimants’ lifetime there will be a substantial savings in the medication costs. Please be aware that this applies to any existing MSAs so this pricing change may warrant a revision in the report.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment